Opus Genetics a clinical-stage biopharmaceutical company, develops and commercializes therapies for patients with ophthalmic disorders.
Opus Genetics(formerly Ocuphire Pharma) has raised $35.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in April 2026.
Opus Genetics(formerly Ocuphire Pharma)'s investors include Balyasny Asset Management, Adage Capital Management, Perceptive Advisors, Oberland Capital, Marshall Wace.
Opus Genetics(formerly Ocuphire Pharma) is headquartered in Farmington Hills, United States.
Opus Genetics a clinical-stage biopharmaceutical company, develops and commercializes therapies for patients with ophthalmic disorders.
Opus Genetics(formerly Ocuphire Pharma) is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Opus Genetics(formerly Ocuphire Pharma) — Funding & Investors." VCBacked, April 6, 2026, https://www.vcbacked.co/company/opus-geneticsformerly-ocuphire-pharma. Accessed August 15, 2026.
VCBacked. (2026). Opus Genetics(formerly Ocuphire Pharma) — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/opus-geneticsformerly-ocuphire-pharma
{{cite web |title=Opus Genetics(formerly Ocuphire Pharma) — Funding & Investors |url=https://www.vcbacked.co/company/opus-geneticsformerly-ocuphire-pharma |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated